Cogent Biosciences (COGT) Non-Current Deffered Revenue (2017 - 2018)
Cogent Biosciences (COGT) recorded quarterly Non-Current Deffered Revenue of $748000.0 in Q4 2018, down 14.12% quarter-over-quarter from $871000.0 in Q3 2018, and down 91.42% on a YoY basis from $8.7 million in Q4 2017.
Cogent Biosciences (COGT) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Cogent Biosciences' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $748000.0 for Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 91.42% year-over-year to $748000.0; the TTM figure through Dec 2018 stood at $748000.0 (down 91.42% YoY), while the FY2018 annual figure was $748000.0, down 91.42% from the prior year.
- Non-Current Deffered Revenue was $748000.0 for Q4 2018 at Cogent Biosciences, down from $871000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $8.7 million in Q4 2017 to a low of $748000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Cogent Biosciences | 5.09 Bn | 4.22 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 748,000.00 |
| Sep 30, 2018 | 871,000.00 |
| Jun 30, 2018 | 888,000.00 |
| Mar 31, 2018 | 3.66 Mn |
| Dec 31, 2017 | 8.71 Mn |